The Vasohibin Family: Novel Regulators of Angiogenesis

Sato, Yasufumi

doi:10.1007/978-3-7091-1428-5_12

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 The gene for human vasohibin-2 is located on chromosome 1q32.3, and its protein is composed of 355 amino acid residues. 7 It has been determined that vasohibin-1 and 2 are highly conserved among different species. 8 Vasohibin-1 is dominantly expressed in endothelial cells in vitro, and its mRNA expression is induced by stimulations with certain angiogenic factors, such as the VEGF/VEGFR2 pathway, and FGF-2 via PKC-d pathway activation.…”

Section: Introductionmentioning

confidence: 99%

Maternal serum vasohibin-1 and vasohibin-2 concentrations in pregnant women diagnosed with late fetal growth restriction or small for gestational age fetus

Bozoklar,

Kale,

Özel

et al. 2024

JCOGP

View full text Add to dashboard Cite

Aims: Vasohibin 1, a member of the vasohibin family, is an inhibitor of angiogenesis, while vasohibin 2 stimulates angiogenesis. Placental expressions of vasohibins and their relationship with preeclampsia have been investigated, but their effects on intrauterine fetal growth are unknown. In this context, we aimed to investigate the concentrations of vasohibin 1 and 2 in the serum of pregnant women diagnosed with late fetal growth restriction (FGR) or small for gestational age (SGA) in the third trimester. Methods: This prospective non-interventional cohort study was conducted on 81 pregnant women, 26 of whom were diagnosed with late FGR, 28 were SGA, and 27 were healthy controls. Three groups were compared in terms of serum vasohibin 1 and 2 concentrations in the third trimester. Results: Three groups were similar in terms of demographic characteristics and gestational age at blood sampling for vasohibin 1 and 2 (p < 0.05). The median vasohibin 1 concentration was determined as 1227.41 ng/mL in the late FGR group, 1311.15 ng/mL in the SGA group, and 1391.38 ng/mL in the control group (p = 0.139). The median vasohibin 2 concentration was determined as 11.24 ng/mL in the late FGR group, 11.86 ng/mL in the SGA group, and 14.34 ng/mL in the control group (p = 0.198). Conclusion: Serum vasohibin 1 and 2 concentrations were found to be similar in pregnant women diagnosed with late FGR and SGA and pregnant women with AGA fetuses. Vasohibin 1 and 2 are involved in the regulation of placental angiogenesis, but their roles in intrauterine fetal growth remain unclear.

show abstract

Section: Introductionmentioning

confidence: 99%

Maternal serum vasohibin-1 and vasohibin-2 concentrations in pregnant women diagnosed with late fetal growth restriction or small for gestational age fetus

Bozoklar,

Kale,

Özel

et al. 2024

JCOGP

View full text Add to dashboard Cite

show abstract

“…Como la respuesta angiogénica surge ante condiciones de hipoxia o isquemia (2) , el VEGF actúa aumentando la permeabilidad vascular y participando como factor antiapoptótico en las células endoteliales de los nuevos vasos formados (3) , promoviendo la potencialidad metastásica del tumor en formación. De sus variantes, el VEGF-A es el factor más importante en la angiogénesis, al estimular la síntesis de proteasas, migración y proliferación de las células endoteliales (4) . Existen estudios donde se bloqueó la expresión del VEGF en cuestión, mediante la utilización de sorafenib y sunitinib, que interactuaban con el receptor de tirosina kinasa KDR o VEGFR-2 (5) , en los cuales disminuyó la angiogénesis.…”

Section: Introductionunclassified

Capacidad antiangiogénica comparada de celecoxib y anticuerpos neutralizantes anti-VEGF en un modelo in vivo

Vargas O.,

Vera N.,

Zerega R.

et al. 2014

Rev. Hosp. Clín. Univ. Chile (En línea)

View full text Add to dashboard Cite

Introduction: A common feature in cancer is the development of angiogenesis, defined as the formation of blood vessels from preexisting ones, highly developed in malignant neoplasms to establish the prevalence of angiogenic factors over anti-angiogenic factors, which in physiological conditions are balanced. While there are currently several antiangiogenic therapies, the compared effect of celecoxib and anti-VEGF antibodies has not been performed on an in vivo model, such as chick chorioallantoid membrane (CAM). Materials and Methods: In this investigation, Methotrexate-resistant TA3 tumor supernatant (TA3-MTX-R) was instilled on the CAM, where a group was also treated with anti-VEGF165 antibodies (20 μg/mL) and another was treated with celecoxib in a concentration of 1000 ppm. Samples were processed histologically and stained with Hematoxylin Eosin-Alcian Blue. Double blind in blood vessels counting was performed using an optical microscope at 400x. Results: Both treatments promote reduced vascular density, where group treated with anti-VEGF antibodies was more antiangiogenic than group treated with celecoxib (p < 0.05). Conclusions: anti-angiogenic anti-VEGF potential and its greater efficacy compared with celecoxib is evident, due to their different mechanisms of action. Future studies should involve the co-adjuvant effect between celecoxib and anti-VEGF in cancer patients resistant to treatment with methotrexate.

show abstract

The Vasohibin Family: Novel Regulators of Angiogenesis

Cited by 2 publications

References 26 publications

Maternal serum vasohibin-1 and vasohibin-2 concentrations in pregnant women diagnosed with late fetal growth restriction or small for gestational age fetus

Maternal serum vasohibin-1 and vasohibin-2 concentrations in pregnant women diagnosed with late fetal growth restriction or small for gestational age fetus

Capacidad antiangiogénica comparada de celecoxib y anticuerpos neutralizantes anti-VEGF en un modelo in vivo

Contact Info

Product

Resources

About